Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and a pioneer in image-guided therapy, announced the launch of Philips UniGuide...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
FAB-KLEAR investigates lucerastat as a potential disease-modifying therapy targeting the kidney manifestations of Fabry disease. Nxera will contribute to ...
GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, announced the achievement of t...
Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President Kos Biotechnology Partners ("Kos"), a global ...
Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease ...
Recipharm expands its sterile manufacturing capacity with a new cream and ointment line at Odivelas, Portugal, able to produce 8 to 15 million units pe...
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-nega...
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, announced results from an independent evaluation of myStage Dx, its CE-IVD...
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy so...
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, softwa...
Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeut...
AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines th...
Ambrose Healthcare, a rare disease specialist, has acquired 100% of the shares of AM-Pharma. Under the terms of the agreement, AM-Pharma's shareholders are...
© 2026 Biopharma Boardroom. All Rights Reserved.
